MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2025.1683070

Медицинская библиотека · Frontiers in immunology · 2025

COVID-19 vaccination induces cross-reactive dengue virus antibodies with altered isotype profiles and in vitro antibody-dependent enhancement.

Reinig Sebastian, Kuo Chin, Huang Sheng-Yu, Hsiung Kuei-Ching, Chen Po-Kai, Ito Etsuro, Lee Ing-Kit, Tsai Ching-Yen, Lin Shu-Min, Shih Shin-Ru

СтатьяПеревод в очереди

Аннотация

BACKGROUND

SARS-CoV-2 infection and COVID-19 vaccination can induce antibodies that cross-react with dengue virus (DENV). Pre-existing IgG antibodies against DENV are known to enhance infection through antibody-dependent enhancement (ADE) via Fcγ receptors. COVID-19 vaccines induce an altered IgG subclass distribution with modified Fcγ receptor affinity. This study investigates the isotype profile of DENV cross-reactive antibodies induced by COVID-19 vaccination and their potential to mediate ADE.

METHODS

We retrospectively collected 271 serum samples from individuals in Taiwan who were either SARS-CoV-2-unvaccinated, vaccinated with 1-3 doses of COVID-19 vaccine, recipients of an Omicron-era booster, or previously recovered from dengue infection. Antibody titers (IgM, IgA, and IgG subclasses 1-4) against SARS-CoV-2 spike (S) glycoprotein and DENV serotype 2 envelope (E) protein were measured by enzyme-linked immunosorbent assay (ELISA). Selective depletion of anti-S or anti-E antibodies was performed to confirm cross-reactivity. ADE activity was assessed in vitro by incubating DENV-2 particles with serum antibodies followed by infection of Fcγ receptor-bearing THP-1 monocytic cells.

RESULTS

Cross-reactive anti-E antibodies in COVID-19-vaccinated individuals were predominantly IgM and IgA, whereas anti-S antibodies in vaccinated individuals and anti-E antibodies in dengue-recovered patients were dominated by IgG1. Low levels of cross-reactive anti-E IgG detected in vaccinated individuals were mainly of the low-affinity IgG2 and IgG4 subclasses. These vaccine-induced cross-reactive antibodies mediated significantly stronger in vitro ADE compared with antibodies from natural DENV infection, particularly after the first or second vaccine dose and after Omicron-variant boosters. Inactivation of complement reduced ADE in COVID-19-vaccinated sera but enhanced it in sera from dengue-recovered individuals.

CONCLUSION

COVID-19 vaccination induces DENV cross-reactive antibodies with a distinct isotype profile and distinct ADE compared with natural dengue infection. Due to low Fc-affinity these antibodies likely do not pose a threat of dengue. These findings highlight the importance of considering off-target immunity and ADE risk in future vaccine design.

Для цитирования: Reinig Sebastian, Kuo Chin, Huang Sheng-Yu, Hsiung Kuei-Ching, Chen Po-Kai, Ito Etsuro, Lee Ing-Kit, Tsai Ching-Yen, Lin Shu-Min, Shih Shin-Ru. COVID-19 vaccination induces cross-reactive dengue virus antibodies with altered isotype profiles and in vitro antibody-dependent enhancement.. Frontiers in immunology. 2025. DOI: 10.3389/fimmu.2025.1683070.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.